the first hybrid closed-loop (hCL) insulin pump and continuous glucose monitoring (CGm) system. integrated with new SmartGuard technology, Guardian(3) CGm sensor and transmitter, this medtronic minimed 670G insulin pump is the first of its kind for automated insulin delivery. The difference between this system and previous systems is notable. educators and providers will need to be educated on this system to help their patients achieve maximum benefits with this technology advancement.
Previous Insulin Pumps
For decades, the cutting-edge technology of the insulin pump, manufactured by a handful of companies, was designed to deliver basal rapid-acting insulin via a subcutaneous cannula (with or without tubing) in small increments according to preset rates. The basal settings can be programmed for numerous different rates per day. This has been a key advantage over injections of background insulin, which deliver a formula-specific amount of insulin over time following an injection. The insulin pump can deliver bolus and correction insulin on demand, in a similar manner as injections. however, it has the advantage of a calculator that uses the preset insulin-carbohydrate ratio (iCr), correction factor (aka sensitivity), blood glucose (BG) target, and current insulin on board (amount of previous remaining bolus) to determine a bolus dose. The calculator requires the amount of carbohydrate and current BG to be entered in the pump to determine the food and correction dose, respectively, and the user can accept or alter the bolus. in recent years, most insulin pump companies have integrated, or linked, CGm with their insulin pump to display the CGm sensor glucose (SG) values on the pump screen. The minimed 670G hCL system automatically adjusts basal insulin rates in real time in response to the SG. The insulin delivered (every 5 minutes) for basal is referred to as micro bolus insulin. Bolus iCr and correction insulin are delivered in similar fashion as previous pumps. For this reason, accurate carbohydrate counting and iCr remain paramount in controlling post-prandial glucose. Bolus dosing prior to eating (rather than during or after) is absolutely needed to prevent hyperglycemia excursions.
Using the minimed 670G system with the SmartGuard hCL algorithm enabled is referred to as auto mode. This is in contrast to using the pump (with or without the CGm) without the automatic features enabled, which is referred to as manual 1 diabetes for at least 2 years and were already using an insulin pump. Baseline measures were collected during a 2-week run-in period when participants used the hCL system in manual mode. insulin and SG data for 6 days following the run-in period were used by the hCL system to establish the initial automatic insulin delivery rates. Participants were free-living during the 3-month study but were required to spend 6 days in a research-controlled "hotel" setting for frequent venous blood glucose collection to evaluate CGm sensor accuracy.
aaDe iN PRactice // September 2018 // 13 over the 12 389 patient-days, no episodes of severe hypoglycemia or diabetic ketoacidosis (dKA) occurred. There were 4 serious adverse events and 117 nonsevere adverse events not related to the hCL system, and 28 adverse events were reported as being related to the system, including skin irritation, rash, hyperglycemia, and severe hyperglycemia. Causes of the severe hyperglycemia were infusion set (11 events), software or hardware issues (5 events), and sensor issues (1 event). See Table 1 
Components of the MiniMed 670G System
The minimed 670G system is newly designed, although its platform is similar to minimed 630G. That is why we need professionals that can be objective, courageous, respectful, and sensitive to those of us that are trying our best to get the job done. (Nicole B.)
An educator working with the hCL system said,
Remember this is a first-of-its-kind of system (exciting but new to everyone). There is a learning curve for patients, professionals, and the industry that makes these systems. We can look forward to continued advancements in the technology. This system is not closed-loop; in other words, it is not fully automatic. But don't let any bumps in the road discourage you or your patients. For instance, the system will ask for additional BGs at times to assure the sensor is on track. This is a requirement for the system to stay in auto Clinical studies being conducted in the US are required to be entered into the US National Library of medicine data base (www.clinicaltrials.gov).
A simple search using the term diabetes closedloop revealed 185 studies that are either planned, actively recruiting, or completed.
Need for Education
We as providers and educators need to learn and understand all the capabilities of this new hCL system so we in turn can help educate our patients. We must identify barriers to the use of 
Conclusion
The minimed 670G hCL system (and future systems) will offer features not previously available.
The differences will need to be appreciated to help guide our patients into this very exciting future. n mamie j. lausch, ms, rn, rDn, CDe, is why do some people with t1D stop using a pump and cgM? https://t1dexchange.org/pages/why-do-somepeople-with-t1d-stop-using-a-pump-and-cgm/. accessed 
